{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:57:56Z","timestamp":1785560276785,"version":"3.56.0"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,8,1]]},"DOI":"10.2169\/internalmedicine.6411-25","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T22:26:39Z","timestamp":1766615199000},"page":"2085-2089","source":"Crossref","is-referenced-by-count":1,"title":["5-Aminosalicylic Acid-induced Colitis in a Patient with Rheumatoid Arthritis without Inflammatory Bowel Disease"],"prefix":"10.2169","volume":"65","author":[{"given":"Ryosuke","family":"Izumi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Chugoku Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chugoku Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Hattori","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chugoku Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Shirane","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chugoku Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirosato","family":"Tamari","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chugoku Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chugoku Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Higashiyama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chugoku Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Kuga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chugoku Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Moriya","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chugoku Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis 16: 2-17, 2022.","DOI":"10.1093\/ecco-jcc\/jjab178"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Mansuri I, Wang S, Fishman L, et al. Clinical outcomes of maintenance therapy with sulfasalazine compared to 5-aminosalicylates in children with ulcerative colitis. J Pediatr Gastroenterol Nutr 80: 988-997, 2025.","DOI":"10.1002\/jpn3.70041"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Rains CP, Noble S, Faulds D. Sulfasalazine: a review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 50: 137-156, 1995.","DOI":"10.2165\/00003495-199550010-00009"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Mikami Y, Tsunoda J, Suzuki S, Mizushima I, Kiyohara H, Kanai T. Significance of 5-aminosalicylic acid intolerance in the clinical course of ulcerative colitis. Digestion 104: 58-65, 2023.","DOI":"10.1159\/000527452"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Liu M, Gu L, Zhang Y, Zhou H, Wang Y, Xu ZX. A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system. Front Pharmacol 15: 1290975, 2024.","DOI":"10.3389\/fphar.2024.1290975"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Svartz N. Salazopyrin, a new sulfanilamide preparation. Acta Med Scand 110: 577-598, 1942.","DOI":"10.1111\/j.0954-6820.1942.tb06841.x"},{"key":"7","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(77)90831-5","volume":"2","author":"AK Azad Khan","year":"1977","unstructured":"7. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2: 892-895, 1977.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Doering J, Begue B, Lentze MJ, et al. Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease. Gut 53: 1632-1638, 2004.","DOI":"10.1136\/gut.2003.037911"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 51: 536-539, 2002.","DOI":"10.1136\/gut.51.4.536"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Fardy JM, Lloyd DA, Reynolds RP. Adverse effects with oral 5-aminosalicyclic acid. J Clin Gastroenterol 10: 635-637, 1988.","DOI":"10.1097\/00004836-198812000-00012"},{"key":"11","unstructured":"11. Munakata A, Yoshida Y, Muto T, et al. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. J Gastroenterol 30: 108-111, 1995."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Mizuno S, Ono K, Mikami Y, et al. 5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis. Intest Res 18: 69-78, 2020.","DOI":"10.5217\/ir.2019.00084"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hiraoka S, Fujiwara A, Toyokawa T, et al. Multicenter survey on mesalamine intolerance in patients with ulcerative colitis. J Gastroenterol Hepatol 36: 137-143, 2021.","DOI":"10.1111\/jgh.15138"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Minagawa Y, Uchiyama K, Takagi T, et al. Retrospective investigation of mesalamine intolerance in patients with ulcerative colitis. J Clin Biochem Nutr 71: 249-254, 2022.","DOI":"10.3164\/jcbn.22-33"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Kapur KC, Williams GT, Allison MC. Mesalazine induced exacerbation of ulcerative colitis. Gut 37: 838-839, 1995.","DOI":"10.1136\/gut.37.6.838"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Xie C, Quan R, Hong F, Zou K, Yan W, Fu Y. The culprit of mesalamine intolerance: case series and literature review. BMC Gastroenterol 19: 138, 2019.","DOI":"10.1186\/s12876-019-1049-2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Gupta MK, Pollack S, Hutchings JJ. Mesalamine induced symptom exacerbation of ulcerative colitis: case report and brief discussion. World J Gastrointest Pharmacol Ther 1: 132-134, 2010.","DOI":"10.4292\/wjgpt.v1.i6.132"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tanaka T, Hirano D, Ishimaru S, Arataki K. Successful treatment of refractory ulcerative colitis with 5-aminosalicylic acid intolerance and biologic therapy resistance using combined granulocyte and monocyte adsorptive apheresis. Cureus 17: e77641, 2025.","DOI":"10.7759\/cureus.77641"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Matsumoto S, Mashima H. Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease. Sci Rep 10: 22176, 2020.","DOI":"10.1038\/s41598-020-79207-z"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Shimodate Y, Takanashi K, Waga E, Fujita T, Katsuki S, Nomura M. Exacerbation of bloody diarrhea as a side effect of mesalamine treatment of active ulcerative colitis. Case Rep Gastroenterol 5: 159-165, 2011.","DOI":"10.1159\/000326931"},{"key":"21","unstructured":"21. Ikehata A, Honta S, Sekino Y, et al. A case of ulcerative colitis with mesalazine intolerance complicated with agranulocytosis and septic shock during salazosulfapyridine administration. Nihon Shokakibyo Gakkai Zasshi (J Jpn Soc Gastroenterol) 120: 764-772, 2023 (in Japanese)."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/15\/65_6411-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:13:48Z","timestamp":1785557628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/15\/65_6411-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":21,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6411-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"article-number":"6411-25"}}